Tempest Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Tempest Therapeutics

08/11/2022 22:06

* Tempest Therapeutics Inc  TPST.OQ  reported a quarterly
adjusted
loss of 66 cents​​ per share for the quarter ended in September.
The mean expectation of four analysts for the quarter was for a
loss of 80 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Tempest Therapeutics Inc's reported EPS for the quarter
was a
loss of 66 cents​.
    * The mean earnings estimate of analysts had risen by
about 9.8%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Tempest Therapeutics Inc shares had risen by 4.6% this
quarter and lost 65.5% so far this year.
    * The company reported a quarterly loss of $8.95 million.
    * Wall Street's median 12-month price target for Tempest
Therapeutics Inc is $10.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
8 at 10:06 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.80          -0.66          Beat
 Jun. 30 2022      -0.92          -0.79          Beat
 Mar. 31 2022      -1.12          -1.18          Missed
 Dec. 31 2021      -1.23          -1.12          Beat